Qsam Biosciences Inc (QSAM) Financials
$8.30
As on 02-May-2024 15:59EDT
Market cap
$37 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
201.6
Div. Yield
0 %
Income Statement ($ Mln) |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
--
|
--
|
--
|
0.79
|
0.92
|
0.03
|
|||||
|
Cost of Revenue
|
--
|
--
|
--
|
372,938.00
|
0.00
|
--
|
|||||
|
Gross Profit
|
--
|
--
|
--
|
-372,938.00
|
0.92
|
0.03
|
|||||
|
Operating Expenses
|
3.94
|
5.46
|
11.04
|
1.32
|
2.08
|
1.61
|
|||||
|
Operating Profit (EBIT)
|
-3.94
|
-5.46
|
-11.04
|
-1.32
|
-1.16
|
-1.58
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Profit before Tax
|
-4.39
|
-5.48
|
-11.98
|
-5.82
|
-0.68
|
-0.40
|
|||||
|
Provision for Tax
|
0.00
|
0.59
|
0.79
|
-0.47
|
1.61
|
0.05
|
|||||
|
Profit after Tax (Net Income)
|
-4.39
|
-6.07
|
-12.77
|
-5.35
|
-2.30
|
-0.40
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
-13.55
|
-4.90
|
-0.72
|
-0.44
|
Liabilities ($ Mln) |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.67
|
-1.22
|
0.28
|
-4.28
|
-3.82
|
-3.26
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
1.00
|
1.20
|
0.53
|
0.11
|
0.03
|
2.96
|
|||||
|
Current Liabilities
|
1.03
|
1.58
|
1.39
|
4.19
|
3.80
|
0.46
|
|||||
|
Total Liabilities
|
1.71
|
0.36
|
1.67
|
0.02
|
0.01
|
0.16
|
Assets ($ Mln) |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
--
|
--
|
0.03
|
0.02
|
--
|
0.00
|
|||||
|
Current Assets
|
1.71
|
0.36
|
1.67
|
0.02
|
0.01
|
0.16
|
|||||
|
Total Assets
|
1.71
|
0.36
|
1.67
|
0.02
|
0.01
|
0.16
|
|||||
|
Total Debt*
|
0.01
|
0.45
|
0.57
|
3.94
|
3.43
|
3.13
|
|||||
|
Net Current Assets
|
0.67
|
-1.22
|
0.28
|
-4.17
|
-3.79
|
-0.30
|
Cashflow ($ Mln) |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-2.85
|
-2.71
|
-1.77
|
-0.74
|
-0.98
|
-1.07
|
|||||
|
Cash Flow from Investing Activities
|
--
|
--
|
--
|
--
|
--
|
-0.05
|
|||||
|
Cash from Financing Activities
|
4.01
|
1.44
|
3.26
|
0.75
|
0.82
|
0.98
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-1.22
|
-3.00
|
-16.24
|
-0.27
|
-1.10
|
-7.87
|
|||||
|
Cash EPS ($)
|
-1.22
|
-3.00
|
-16.24
|
-0.27
|
-1.10
|
-7.86
|
|||||
|
Adjusted Book Value ($)
|
0.19
|
--
|
0.35
|
--
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
-0.79
|
-1.34
|
-2.25
|
-0.04
|
-0.47
|
-21.16
|
|||||
|
Free Cash Flow per Share ($)
|
-0.79
|
-1.34
|
-2.25
|
-0.04
|
-0.47
|
-21.16
|
Profitability Ratios |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
10,415.06
|
-13,868.48
|
-4,939.80
|
1,460.21
|
863.71
|
-1,584.84
|
|||||
|
ROE (%)
|
1,617.91
|
1,294.60
|
638.21
|
132.14
|
64.83
|
12.20
|
|||||
|
ROA (%)
|
-424.48
|
-597.19
|
-1,509.77
|
-36,486.28
|
-2,724.89
|
-170.70
|
|||||
|
EBIT Margin (%)
|
--
|
--
|
--
|
-168.65
|
-126.76
|
-3.72
|
|||||
|
Net Margin (%)
|
--
|
--
|
--
|
-681.65
|
-250.49
|
-1,191.78
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
-1.00
|
-0.14
|
26.50
|
-0.55
|
|||||
|
EBIT Growth (%)
|
27.74
|
50.54
|
-733.68
|
-13.98
|
-93,606.85
|
99.95
|
|||||
|
Net Profit Growth (%)
|
27.68
|
52.41
|
-138.47
|
-133.13
|
-478.00
|
85.39
|
|||||
|
EPS Growth (%)
|
0.59
|
0.81
|
-58.18
|
0.75
|
0.86
|
0.86
|
|||||
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
-5.01
|
-1.41
|
-0.01
|
-1.86
|
-0.01
|
0.00
|
|||||
|
Price / Book Value
|
32.75
|
-7.07
|
0.51
|
-2.33
|
-0.01
|
0.00
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-5.23
|
-1.62
|
0.07
|
-3.09
|
-33.22
|
-2,849.39
|
|||||
|
Close Price ($)
|
6.10
|
4.25
|
7.20
|
20.40
|
9.40
|
24.70
|
|||||
|
High Price ($)
|
7.50
|
14.00
|
84.00
|
35.00
|
68.00
|
118.00
|
|||||
|
Low Price ($)
|
3.51
|
3.50
|
5.88
|
6.00
|
5.10
|
14.10
|
|||||
|
Market Cap ($ Cr)
|
--
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
0.01
|
-0.37
|
2.08
|
-0.92
|
-0.90
|
-0.96
|
|||||
|
Short term debt to equity ratio
|
0.01
|
-0.37
|
2.08
|
-0.90
|
-0.89
|
-0.05
|
|||||
|
Current Ratio
|
1.65
|
0.23
|
1.20
|
0.01
|
0.00
|
0.35
|
|||||
|
Quick Ratio
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Interest Coverage
|
-74.90
|
-73.41
|
-14.00
|
-2.70
|
-2.09
|
0.00
|
Operating Efficiency Ratios |
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
--
|
--
|
--
|
53.53
|
10.88
|
0.14
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Payable days
|
--
|
--
|
--
|
0.00
|
210,004.82
|
--
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|